innoscripta SE (ISIN: DE000A40QVM8) has launched operations in the United Kingdom, continuing its international expansion following a successful market entry into France earlier this year. The company has established a dedicated local sales team and already secured its first UK customer: a software company with annual revenues in the mid-double-digit million euro range that has selected innoscripta's SaaS platform Clusterix to support its R&D tax relief claims.
Clusterix enables companies to systematically capture R&D projects, working hours and eligible costs while creating a comprehensive, audit-ready documentation trail. This capability is increasingly important as HM Revenue & Customs (HMRC) has substantially tightened documentation and compliance requirements for R&D tax relief claims in recent years. The platform has been fully adapted to UK regulatory requirements.
According to the company, several additional customer engagements are at an advanced stage of negotiations, and innoscripta plans to significantly expand both its UK sales organization and customer base by the end of the year. The UK represents a market roughly seven times larger than Germany, with annual R&D tax reliefs of approximately EUR 8.7 billion (around 0.3% of GDP), making it one of Europe's largest R&D tax incentive markets alongside France.
This expansion underscores the growing importance of specialized software for managing R&D tax credits amid stricter regulatory oversight. The UK market's size and the increasing complexity of compliance create a significant opportunity for innoscripta's platform. As noted in the company's press release, the move follows innoscripta's successful entry into France earlier in 2026.
innoscripta SE offers Clusterix as a scalable software platform for the structured organization and management of research and development activities. Companies use Clusterix to efficiently manage innovation projects, digitize internal processes, and make their R&D activities transparent and scalable. The company's international expansion strategy aims to capture market share in Europe's largest R&D tax incentive markets.
